CD28z CARs and armored CARs Journal Article


Authors: Pegram, H. J.; Park, J. H.; Brentjens, R. J.
Article Title: CD28z CARs and armored CARs
Abstract: CD19-targeted chimeric antigen receptor (CAR) T cells are currently being tested in the clinic with very promising outcomes. However, limitations to CAR T cell therapy exist. These include lack of efficacy against some tumors, specific targeting of tumor cells without affecting normal tissue and retaining activity within the suppressive tumor microenvironment. Whereas promising clinical trials are in progress, preclinical development is focused on optimizing CAR design, to generate "armored CAR T cells," which are protected from the inhibitory tumor microenvironment. Studies investigating the expression of cytokine transgenes, combination therapy with small molecule inhibitors, or monoclonal antibodies, are aimed at improving the antitumor efficacy of CAR T cell therapy. Other strategies aimed at improving CAR T cell therapy include using dual CARs and chemokine receptors to more specifically target tumor cells. This review will describe the current clinical data and some novel armored CAR T cell approaches for improving antitumor efficacy therapy. Copyright © 2014 Lippincott Williams & Wilkins.
Keywords: chimeric antigen receptor (car); "armored car t cells"; antitumor efficacy therapy
Journal Title: The Cancer Journal
Volume: 20
Issue: 2
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2014-03-01
Start Page: 127
End Page: 133
Language: English
DOI: 10.1097/ppo.0000000000000034
PROVIDER: scopus
PUBMED: 24667958
PMCID: PMC4687893
DOI/URL:
Notes: Export Date: 1 May 2014 -- CODEN: CAJOC -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Renier J Brentjens
    269 Brentjens
  2. Jae Hong Park
    223 Park
  3. Hollie Jaine Pegram
    19 Pegram